index - Epidemiology in dermatology and evaluation of therapeutics Accéder directement au contenu

DOCUMENTS

79

 

NOTICES

153

 

 

MOTS CLES

Antibiotic misuse Placebo Biosimilar Pharmaceuticals Accelerometer Alcohol Anti-TNF Prostate cancer Cardiotoxicity Cardiomyopathy Apremilast Antimicrobiens ArtThese Adalimumab Quality of life Cattle Ankylosing spondylitis Spondyloarthritis Auto-immune hepatitis Immunotherapy Psoriasis Anticancer drugs Case-Control Studies Anxiété Bacterial rhinosinusitis Biological therapy Angiotensin receptor blockers Biological Therapy Albinism Sacroiliitis Immune checkpoint inhibitors Méta-Analyse Immune-related adverse events Endocrine toxicity Biologic drug Adverse side effects Anti-HCV Direct Acting Antivirals DAA Arthritis Cardio-oncology Beta-lactam antibiotics CTLA-4 Calcium channel blockers Arrhythmia Cardiovascular risk Autoimmunity BTK protein Apre-milast Antimicrobial resistance Epidemiology Psoriatic arthritis Amyloidosis Abus d'antibiotiques Intensive care Drug survival Stability Vigibase® Management Anxiety Atrial fibrillation Burden Atopic dermatitis Ustekinumab Ethics Addiction Drug reaction Angiotensin-converting enzyme inhibitors Axial spondyloarthritis Care pathway Access to care Acute Myeloid Leukaemia AML Biologics CSK tyrosine-protein kinase Antibiotics Azathioprine Autoimmune diseases Auto-Diagnostic Etanercept Aging Dermatology COVID-19 Pharmacoepidemiology Meta-Analysis Cardiovascular therapy Glucocorticoids Primary adrenal insufficiency Biologic therapy Adolescent Antibiotic resistance Treatment Alitretinoin Ankylosing Infliximab Cancer ASDAS Biomédicaments Biologic Pharmacovigilance Graft-versus-host disease Sipuleucel-T Biomarkers Antimicrobials

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS